Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Aug;26(4):483-9.
doi: 10.1007/s00540-012-1363-0. Epub 2012 Mar 2.

The effect of dexmedetomidine on arterial-cardiac baroreflex function assessed by spectral and transfer function analysis

Affiliations
Randomized Controlled Trial

The effect of dexmedetomidine on arterial-cardiac baroreflex function assessed by spectral and transfer function analysis

Toru Ehara et al. J Anesth. 2012 Aug.

Abstract

Purpose: The α(2)-adrenergic receptor agonist dexmedetomidine reportedly weakens heart rate (HR) responses to 'rapid' (during a few seconds) reduction in arterial pressure, but does not affect HR responses to 'gradual' (during 60 s) reduction in arterial pressure. As the speed of neurotransmission along the parasympathetic nerve is relatively rapid, alteration of parasympathetic-mediated arterial-cardiac baroreflex function plays a more important role in HR responses to 'rapid' changes in arterial pressure. We therefore hypothesized that dexmedetomidine attenuates parasympathetic-mediated arterial-cardiac baroreflex function.

Methods: Twelve healthy men received placebo, low-dose (loading, 3 μg/kg/h for 10 min; maintenance, 0.2 μg/kg/h for 60 min) (low-DEX), or moderate-dose (loading, 6 μg/kg/h for 10 min; maintenance, 0.4 μg/kg/h for 60 min) (moderate-DEX) dexmedetomidine infusions in a randomized, double-blind, crossover study. Before and after 70 min of infusion, arterial-cardiac baroreflex function was assessed by spectral and transfer function analysis between arterial pressure variability and HR variability.

Results: The high-frequency power of systolic arterial pressure (SAP) variability increased significantly with low-DEX and moderate-DEX infusions (significant interaction effects, P = 0.005), whereas the high-frequency power of R-wave-R-wave interval (RRI) variability (as an index of cardiac parasympathetic activity) did not change significantly at any dose infusions. Then, transfer function gain in the high-frequency range (as an index of parasympathetic arterial-cardiac baroreflex) decreased significantly with low-DEX and moderate-DEX infusions (significant interaction effects, P = 0.007).

Conclusions: The present results suggest that dexmedetomidine attenuates parasympathetic-mediated arterial-cardiac baroreflex function, implying weakened HR response to 'rapid' reduction in arterial pressure.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Hypertens. 2006 Feb;24(2):345-52 - PubMed
    1. Am J Physiol. 1991 Oct;261(4 Pt 2):H1231-45 - PubMed
    1. Hypertension. 1993 Feb;21(2):236-47 - PubMed
    1. Anesthesiology. 2000 Aug;93(2):382-94 - PubMed
    1. Anesthesiology. 2002 Sep;97(3):592-8 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources